SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, today reported positive data from a multicenter clinical study (NCT 04708951) comparing the adenoma detection rate (ADR) of its FDA-cleared G-EYE® balloon technology against ENDOCUFF VISION® (ECV) technology in patients undergoing screening or surveillance colonoscopy. Results from this randomized trial, the first head-to-head comparison of these two colonoscopy mechanical enhancement devices, showed that the ADR, particularly for advanced and large adenomas, was higher for the G-EYE® balloon than for the ECV attachment. Seth Gross, MD, Professor, Department of Medicine at NYU Grossman School of Medicine, Clinical Chief, Division of Gastroenterology and Hepatology at NYU Langone Health, and co-author on the abstract, presented the data in an oral session at ACG 2021, which is taking place October 22-27 in Las Vegas (ACG 2021, Presidential Plenary Session 1, Abstract #S233).
Trending
- Experts weigh in on liability over AI use in healthcare (Healio)
- Ascension’s Outpatient Surgery Volume Rose Nearly 400% After AMSURG Buy (ASC News)
- CMS Finalizes Reassignment of Gastric Alimetry® Test to Higher Payment Level, Increasing Medicare Hospital Outpatient Payment by Approximately 144% (Globe Newswire )
- MedInTech Secures $25.7 Million for AI Robotics Expansion (DistilINFO)
- AI-assisted colonoscopy and disease-specific imaging show benefits in ulcerative colitis (Hospital Healthcare Europe)
- The race to understand why young people are dying from colon cancer (Scientific American)
- What the Robot Still Can’t Do (NEJM)
- Geneoscopy Resolves Patent and False Advertising Litigation with Exact Sciences Following a Series of Victories at the Patent Trial and Appeal Board (PR Newswire)
